Journal article

IL-10 in glioma

Samuel S Widodo, Marija Dinevska, Liam M Furst, Stanley S Stylli, Theo Mantamadiotis



The prognosis for patients with glioblastoma (GBM), the most common and malignant type of primary brain tumour, is very poor, despite current standard treatments such as surgery, radiotherapy and chemotherapy. Moreover, the immunosuppressive tumour microenvironment hinders the development of effective immunotherapies for GBM. Cytokines such as interleukin-10 (IL-10) play a major role in modulating the activity of infiltrating immune cells and tumour cells in GBM, predominantly conferring an immunosuppressive action; however, in some circumstances, IL-10 can have an immunostimulatory effect. Elucidating the function of IL-10 in GBM is necessary to better strategise and improve the efficacy of..

View full abstract


Awarded by National Health & Medical Research Council MRFF Accelerated Research

Funding Acknowledgements

This work was funded by the National Health & Medical Research Council MRFF Accelerated Research (APP1158175), Australian Brain Cancer Mission, Cancer Australia (to S.S.S.), the Department of Surgery Seed Funding, the Department of Microbiology and Immunology, The University of Melbourne, the CASS Foundation and the Brain Foundation Australia.